# A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies

> **NCT07569029** · PHASE1 · NOT_YET_RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 42 (estimated)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** DV700P-RNA 100 mcg
- **BIOLOGICAL:** DV701B1.1-RNA 100 mcg

## Key facts

- **NCT ID:** NCT07569029
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-02
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07569029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07569029, "A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07569029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*